Literature DB >> 27584931

Current status of alloimmunity.

Thiago J Borges1, Naoka Murakami, Leonardo V Riella.   

Abstract

PURPOSE OF REVIEW: The present review aims to highlight the major recent advances in transplantation with regards to basic, translational, and clinical research. RECENT
FINDINGS: We describe new concepts in understanding allorecognition and allospecificity of T cells, and discuss current challenges in targeting memory T cells, including the limitation of rodent disease models. From a clinical perspective, we highlight the advances in molecular biopsy characterization, which have expanded our knowledge of potential drivers of injury and may provide better parameters for patient risk stratification. We also highlight the dual role of innate immunity in both stimulating and regulating adaptive immunity, as well as novel insights into environmental exposures that may affect immune regulation, such as high-salt diet. Finally, we discuss advances in understanding humoral response and novel technologies, such as chimeric antigen receptors-engineered T cells, microparticle-based drug delivery, and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) gene editing, that may provide intriguing and promising approaches to restrain alloimmunity.
SUMMARY: Current advances in our understanding of the basic mechanisms of alloimmunity and their potential translation to clinical applications will permit the development of novel diagnostic and therapeutic strategies to improve long-term graft survival.

Entities:  

Mesh:

Year:  2016        PMID: 27584931      PMCID: PMC5081243          DOI: 10.1097/MNH.0000000000000267

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  43 in total

Review 1.  DC-SIGN, a C-type lectin on dendritic cells that unveils many aspects of dendritic cell biology.

Authors:  Teunis B H Geijtenbeek; Anneke Engering; Yvette Van Kooyk
Journal:  J Leukoc Biol       Date:  2002-06       Impact factor: 4.962

2.  Using Molecular Phenotyping to Guide Improvements in the Histologic Diagnosis of T Cell-Mediated Rejection.

Authors:  J Reeve; J Chang; I D R Salazar; M Merino Lopez; P F Halloran
Journal:  Am J Transplant       Date:  2016-01-05       Impact factor: 8.086

3.  Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes.

Authors:  B D Modena; S M Kurian; L W Gaber; J Waalen; A I Su; T Gelbart; T S Mondala; S R Head; S Papp; R Heilman; J J Friedewald; S M Flechner; C L Marsh; R S Sung; H Shidban; L Chan; M M Abecassis; D R Salomon
Journal:  Am J Transplant       Date:  2016-03-15       Impact factor: 8.086

4.  Complement-binding anti-HLA antibodies and kidney-allograft survival.

Authors:  Alexandre Loupy; Carmen Lefaucheur; Dewi Vernerey; Christof Prugger; Jean-Paul Duong van Huyen; Nuala Mooney; Caroline Suberbielle; Véronique Frémeaux-Bacchi; Arnaud Méjean; François Desgrandchamps; Dany Anglicheau; Dominique Nochy; Dominique Charron; Jean-Philippe Empana; Michel Delahousse; Christophe Legendre; Denis Glotz; Gary S Hill; Adriana Zeevi; Xavier Jouven
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

5.  Belatacept and Long-Term Outcomes in Kidney Transplantation.

Authors:  Flavio Vincenti; Lionel Rostaing; Joseph Grinyo; Kim Rice; Steven Steinberg; Luis Gaite; Marie-Christine Moal; Guillermo A Mondragon-Ramirez; Jatin Kothari; Martin S Polinsky; Herwig-Ulf Meier-Kriesche; Stephane Munier; Christian P Larsen
Journal:  N Engl J Med       Date:  2016-01-28       Impact factor: 91.245

6.  Quantifying Memory CD8 T Cells Reveals Regionalization of Immunosurveillance.

Authors:  Elizabeth M Steinert; Jason M Schenkel; Kathryn A Fraser; Lalit K Beura; Luke S Manlove; Botond Z Igyártó; Peter J Southern; David Masopust
Journal:  Cell       Date:  2015-05-07       Impact factor: 41.582

7.  Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.

Authors:  Naoka Murakami; Thiago J Borges; Michifumi Yamashita; Leonardo V Riella
Journal:  Clin Kidney J       Date:  2016-05-04

8.  Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft.

Authors:  Muhammad M Mohiuddin; Avneesh K Singh; Philip C Corcoran; Marvin L Thomas Iii; Tannia Clark; Billeta G Lewis; Robert F Hoyt; Michael Eckhaus; Richard N Pierson Iii; Aaron J Belli; Eckhard Wolf; Nikolai Klymiuk; Carol Phelps; Keith A Reimann; David Ayares; Keith A Horvath
Journal:  Nat Commun       Date:  2016-04-05       Impact factor: 14.919

9.  Targeted Delivery of Immunomodulators to Lymph Nodes.

Authors:  Jamil Azzi; Qian Yin; Mayuko Uehara; Shunsuke Ohori; Li Tang; Kaimin Cai; Takaharu Ichimura; Martina McGrath; Omar Maarouf; Eirini Kefaloyianni; Scott Loughhead; Jarolim Petr; Qidi Sun; Mincheol Kwon; Stefan Tullius; Ulrich H von Andrian; Jianjun Cheng; Reza Abdi
Journal:  Cell Rep       Date:  2016-04-28       Impact factor: 9.423

10.  Diversity of the CD4 T Cell Alloresponse: The Short and the Long of It.

Authors:  Jason M Ali; Margaret C Negus; Thomas M Conlon; Ines G Harper; M Saeed Qureshi; Reza Motallebzadeh; Richard Willis; Kourosh Saeb-Parsy; Eleanor M Bolton; J Andrew Bradley; Gavin J Pettigrew
Journal:  Cell Rep       Date:  2016-01-21       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.